Quantitative JAK2 V617F Mutation Molecular Detection
Desired Epic Build
* = editable field
| Cerner Primary Mnemonic: | HLX JAK-2 Mutation CASE |
| PDM | 5160105 |
| Informatics - Workgroup | Molpath inhouse |
| Synonyms * | 221 HLX JAK-2 Mutation CASE MPN JAK2, mutant JAK2 V617F allelic burden, BCR-ABL1 negative testing |
| Display Name * | Quantitative JAK2 V617F Mutation Molecular Detection |
| Specimen Sources (combined Order Entry and Specimen Navigator) * |
Bone Marrow
|
| Specimen Types (combined Order Entry and Specimen Navigator) * |
Bone Marrow
Blood
|
| Body Fluids (types sent through AOEs) | |
| Specimen Navigator Specimen Types |
Aspirate
|
| Specimen Navigator Specimen Sources |
Isthmus
Left
Nasal
No Laterality
Right
Total
Abdomen/Peritoneum
Abscess
Adrenal
Amniotic Sac
Anus
Appendix
Axilla
Bile Duct
Bone
Bone Marrow
Brain
Breast
Bronchial
Buccal
Colon
Duodenum
Ear
Esophagus
Extranodal Lymphoid
Eye
Fallopian Tube
Gallbladder
Gingiva
Ileum
Jejunum
Joint
Kidney
Larynx
Liver
Lung
Lymph Node
Mediastinum
Meninges/Dura
Misc
Muscle
Nasopharynx
Nipple
Nose
Oropharynx/Throat
Ovary
Palate
Pancreas
Pancreatic Duct
Parathyroid
Paratubal Cyst
Pelvic
Penis
Pericardium
Pharynx
Pleura
Prostate
Rectum
Retroperitoneum
Salivary Gland
Sinus
Skin
Soft Tissue
Spleen
Stomach
Testis
Thymus
Thyroid
Tongue
Tonsil
Trachea
Uterus
Vagina
Vas Defe
|
| Specimen Navigator Short Name | JAK2 V617F Quantitative |
| Ordering info (EPIC SmartText) | Myeloproliferative disorders (MPD) are believed to originate through transformation in hematopoietic stem cells (1). Polycythemia vera (PV), essential thrombocythemia (ET), and idiopathic myelofibrosis (IMF) are three main Ph-negative MPDs; these share many characteristics such as marrow hyper-cellularity, risk for thrombosis and hemorrhage and transformation to leukemia.Recent studies on activated tyrosine kinases and signaling through Janus kinases have led to the identification of an acquired point mutation, G1849T in exon 14, in Janus kinase-2 (JAK2) gene in several patients with MPD. In fact, this mutation, V617F, in which phenylalanine is substituted for valine at position 617 has been reported in 95% of patients with PV, and in about 50 to 60% of patients with ET and IMF. This mutation is also reported in a few patients with other MPD conditions and Acute nonlymphocytic leukemia (ANLL), but not reported in patients with lymphoid malignancies, or Chronic myelogenous leukemia (CML). |
| IP Orderable (inpatient) | Yes |
| OP Orderable (outpatient) | Yes |
| AOEs * | |
| AP AOEs | |
| Special History | Yes |
| Build Comments | |
| Filter * | genetics |
| Cerner Site Restrict | |
| Cerner Results | |
Actual Epic Build 3/11/2025
| PROCEDURE ID | 115143 | ||||||||||||
| PDM | 5160105 | ||||||||||||
| ORDER DISPLAY NAME | Quantitative JAK2 V617F Molecular Detection | ||||||||||||
| PROCEDURE NAME | JAK2 MUTATION | ||||||||||||
| PROCEDURE MASTER NUMBER | LAB11401 | ||||||||||||
| SHORT PROCEDURE NAME | JAK2 MUTATION | ||||||||||||
| CATEGORY CODE | 21.0 | ||||||||||||
| CATEGORY CODE RECORD NAME | LAB MOLECULAR DIAGNOSTICS ORDERABLES | ||||||||||||
| SYNONYMS | 221 HLX JAK-2 MUTATION CASE MPN JAK2, MUTANT JAK2 V617F ALLELIC BURDEN, BCR-ABL1 NEGATIVE TESTING |
||||||||||||
| CLINICALLY ACTIVE | Yes | ||||||||||||
| ORDERABLE | Yes | ||||||||||||
| PERFORMABLE | Yes | ||||||||||||
| FILTER GENOMICS | Generic Genomics Procedure | ||||||||||||
| REFERENCE LINK URL | https://labs.northwell.edu/epic/test/115143 | ||||||||||||
| ORDERING INSTRUCTIONS | |||||||||||||
| DEFAULT SPECIMEN TYPE | Blood | ||||||||||||
| SPECIMEN TYPE PICK LIST | Bone Marrow Blood Aspirate |
||||||||||||
| SPECIMEN TYPE LIST | |||||||||||||
| OP SPECIMEN TYPE LIST | |||||||||||||
| SPECIMEN SOURCE PICK LIST | Bone Marrow Aspirate Blood, Arterial Blood, Capillary Blood, Central Line Blood, Venous Bone Marrow |
||||||||||||
| SPECIMEN SOURCE DEFAULT - MALE | Blood, Venous | ||||||||||||
| SPECIMEN SOURCE DEFAULT - FEMALE | Blood, Venous | ||||||||||||
| SPECIMEN SOURCE LIST | |||||||||||||
| OP SPECIMEN SOURCE LIST | |||||||||||||
| IP LAB TEST COMPONENTS FOR REPORT | HLXJAK2FR:10 | ||||||||||||
| OP LAB TEST COMPONENTS FOR REPORT | HLXJAK2FR:10 | ||||||||||||
| ORDER QUESTIONS | ["3048500000"] | ||||||||||||
| ORDER QUESTIONS RECORD NAME | |||||||||||||
| INPATIENT ORDER QUESTIONS | ["3048500000"] | ||||||||||||
| INPATIENT ORDER QUESTIONS RECORD NAME | |||||||||||||
| ORDER SPECIFIC QUESTION OVERRIDE | |||||||||||||
| INPATIENT QUESTION OVERRIDE | |||||||||||||
| LOCATION RESTRICT LIST IP | |||||||||||||
| LOCATION RESTRICT LIST IP RECORD NAME | |||||||||||||
| LOCATION RESTRICT LIST INCLUDE IP | |||||||||||||
| LOCATION RESTRICT LIST OP | |||||||||||||
| LOCATION RESTRICT LIST OP RECORD NAME | |||||||||||||
| LOCATION RESTRICT LIST INCLUDES OP | |||||||||||||
| EDP AMB ORDER SPECIFIC QUESTIONS RECORD NAME | NH IP PATIENT COMPLETED CONSENT | ||||||||||||
| EDP IP ORDER SPECIFIC QUESTIONS RECORD NAME | NH IP PATIENT COMPLETED CONSENT | ||||||||||||
| EDP IP SPECIMEN SOURCE | |||||||||||||
| EDP OP SPECIMEN SOURCE | |||||||||||||
| EDP IP SPECIMEN TYPE | |||||||||||||
| EDP OP SPECIMEN TYPE | |||||||||||||
| DERIVED EDP IP BUTTONS S | |||||||||||||
| DERIVED EDP IP BUTTONS T | |||||||||||||
| DERIVED EDP OP BUTTONS S | |||||||||||||
| DERIVED EDP OP BUTTONS T | |||||||||||||
| IP ORDERABLE | 1 | ||||||||||||
| OP ORDERABLE | 1 | ||||||||||||
| STANDARD LAB COMPONENTS | |||||||||||||
| STANDARD LAB COMPONENTS RECORD NAME | |||||||||||||
| COMPONENT DATA REQUIREMENT | |||||||||||||
EPIC OP AOEs
| |||||||||||||
EPIC IP AOEs
| |||||||||||||
| EPIC Components (results - crosswalked through Cerner) | |||||||||||||